FDA Setting “Vigilance” Standards For Track And Track Process
This article was originally published in The Pink Sheet Daily
Draft guidance lists scenarios where stakeholders should exhibit heightened suspicion that product could be suspect or illegitimate.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.
However, the month may be losing its influence over the US FDA's annual submission total.